SLC5A2 and chronic kidney disease: Therefore, we conducted a meta-analysis of this randomized controlled trials (RCTs) to determine the effects of SGLT2 inhibitors on eGFR, UACR and AKI compared to with placebo or other antidiabetic treatments in patients with T2DM and CKD.